Abstract 75P
Background
The sodium-dependent phosphate transporter NaPi2b is a promising target for the treatment of malignant tumors due to its increased expression in several oncological diseases. NaPi2b is a target for therapeutic monoclonal antibodies directed against the MX35 epitope within the large extracellular domain (ECD) of the NaPi2b. We assume that this epitope has tumor-specific conformation that is formed due to the creation of disulfide bonds between four cysteine residues at positions 303, 322, 328 and 350. The proline residue at position 325 lies between cysteines 322 and 328 in the region of the MX35 epitope of NaPi2b. We assume that proline at this position due to its formation of a bend in the structure of the peptide participates in the formation of a disulfide bond between cysteines at positions 322 and 328 that is critical in the recognition of the MX35 epitope by antibodies. To verify this, the mutant form with the proline replacement should be evaluated using antibodies against the MX35 epitope in Western blot and microscopy analysis. The aim of this work was to create a genetic construct encoding the mutant form of the NaPi2b transporter with the replacement of proline with alanine at position 325.
Methods
To carry out site-directed mutagenesis, we selected primers with the replacement of triplets encoding proline at position 325 with a triplet encoding alanine in the SLC34A2 (encoding transporter NaPi2b) gene. The resulting PCR product was transformed into E.coli cells of the XL1-Blue strain and plasmid DNA was isolated. To confirm the mutation, samples were sequenced using the Sanger method.
Results
As a result of our work, we created a genetic construct with the replacement of proline with alanine at position 325 of the NaPi2b transporter, which will be further test in Western blot and microscopy analysis by monoclonal antibodies.
Conclusions
The obtained results supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030) are important for further study of the mechanism of recognition of the MX35 NaPi2b epitope by monoclonal antibodies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Research Laboratory \"Biomarker\", Institute of Fundamental Medicine and Biology, Kazan Federal University.
Funding
This work has been supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Heterogeneous characteristics of KRAS mutation subtypes in surgically resected lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - ATRX-deficient IDH-wildtype adult high-grade gliomas display novel, clinically relevant genetic patterns by comprehensive genomic profiling
Presenter: Gábor Bedics
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
Presenter: Silvia Teresa Riva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations
Presenter: Greydon Arthur
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype
Presenter: Mohamed abd naceur AMMAR
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Unraveling methylation signatures in RAS/BRAF wild-type colorectal cancer patients to identify predictive biomarkers for anti-epidermal growth factor receptor therapy
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - Spindle cell sarcomas with tyrosine kinase rearrangement
Presenter: Lenka Krsková
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Presenter: Ioanna Mavrommatis
Session: Cocktail & Poster Display session
Resources:
Abstract